Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis

Brett T. Venker, Beejal R. Ganti, Hannah Lin, Elizabeth D. Lee, Ryan M. Nunley, Brian F. Gage

Research output: Contribution to journalReview article

28 Scopus citations

Abstract

Background Venous thromboembolism (VTE) is a common and potentially fatal complication of arthroplasty. Methods We reviewed randomized trials to determine which anticoagulant has the best safety and efficacy in hip and knee arthroplasty patients. We searched PubMed, MEDLINE, and EMBASE through January 2016. Results Compared to enoxaparin (most commonly dosed 40 mg once daily), the relative risk (RR) of VTE was lowest for edoxaban 30 mg once daily (0.49; 95% confidence interval [CI], 0.32-0.75), fondaparinux 2.5 mg once daily (0.53; 95% CI, 0.45-0.63), and rivaroxaban 10 mg once daily (0.55; 95% CI, 0.46-0.66), and highest for dabigatran 150 mg once daily (1.19; 95% CI; 0.98-1.44). The RR of major/clinically relevant bleeding was lowest for apixaban 2.5 mg twice daily (0.84; 95% CI; 0.70-0.99) and highest for rivaroxaban (1.27; 95% CI, 1.01-1.59) and fondaparinux (1.64; 95% CI, 0.24-11.35). Fondaparinux was the only agent that was more effective than enoxaparin 30 mg twice daily (VTE RR = 0.58; 95% CI, 0.43-0.76). Conclusion With the possible exception of apixaban, newer anticoagulants that lower the risk of postoperative VTE increase bleeding.

Original languageEnglish
Pages (from-to)645-652
Number of pages8
JournalJournal of Arthroplasty
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • anticoagulant
  • arthroplasty
  • bleed
  • deep vein thrombosis
  • meta-analysis
  • thromboembolism

Fingerprint Dive into the research topics of 'Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis'. Together they form a unique fingerprint.

  • Cite this